We did a comprehensive review of industry news in 2022Q1 (there was.. a lot of stuff to cover). This article highlights companies focused on drug discovery that IPO’d in the first quarter.
The Drug Discovery IPO Market Slowdown
As everyone knows, biotech’s been in a bear market since Feb. 2021 (with the entire $XBI index down more than 50% since its peak). Record numbers of companies are valued below cash on hand, implying the average investor expects all of that cash to be spent with little return on investment.
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
